arGEN-X awarded €1.5 million IWT grant to advance the application of NHance Fc modifications in therapeutic antibodies
arGEN-X N.V. announced that it has received a € 1.5 million grant from the Institute for the Promotion of Innovation by Sciences and Technology in Flanders (IWT). This grant will be used to advance and commercialize the application of the NHance® Fc modifications in therapeutic antibodies.
“We are very pleased to have received this support from IWT. As an organization, IWT has enabled the steady build of highly competitive Flemish biotechnology companies and we hope to continue this reputation with the advancement of our own novel, cutting edge research. NHance® is our proprietary approach to prolonging antibody circulation time. With the IWT grant, we aim to further confirm the benefit of antibodies equipped with NHance® by demonstrating enhanced tissue and tumor penetration with select antibody candidates in murine disease models,” commented Michael Saunders, Senior Director, Targets & Programs at arGEN-X. “In addition, efficient sweeping of the disease target by Fc modified antibodies can be further explored as NHance® has the game changing benefit of enhanced clearance of the target while the recycled antibody can be used for renewed target binding.”
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous